These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18552131)

  • 1. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery.
    Kuwano K; Hashino A; Noda K; Kosugi K; Kuwabara K
    J Pharmacol Exp Ther; 2008 Sep; 326(3):691-9. PubMed ID: 18552131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries.
    Fuchikami C; Murakami K; Tajima K; Homan J; Kosugi K; Kuramoto K; Oka M; Kuwano K
    Eur J Pharmacol; 2017 Jan; 795():75-83. PubMed ID: 27919660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug.
    Kuwano K; Hashino A; Asaki T; Hamamoto T; Yamada T; Okubo K; Kuwabara K
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1181-8. PubMed ID: 17545310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.
    Morrison K; Studer R; Ernst R; Haag F; Kauser K; Clozel M
    J Pharmacol Exp Ther; 2012 Dec; 343(3):547-55. PubMed ID: 22918043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
    Gatfield J; Menyhart K; Wanner D; Gnerre C; Monnier L; Morrison K; Hess P; Iglarz M; Clozel M; Nayler O
    J Pharmacol Exp Ther; 2017 Jul; 362(1):186-199. PubMed ID: 28476928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.
    Morrison K; Ernst R; Hess P; Studer R; Clozel M
    J Pharmacol Exp Ther; 2010 Oct; 335(1):249-55. PubMed ID: 20660124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery.
    Morrison K; Haag F; Ernst R; Iglarz M; Clozel M
    J Pharmacol Exp Ther; 2018 Jun; 365(3):727-733. PubMed ID: 29588339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins.
    Orie NN; Ledwozyw A; Williams DJ; Whittle BJ; Clapp LH
    Prostaglandins Other Lipid Mediat; 2013 Oct; 106():1-7. PubMed ID: 23872196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
    Asaki T; Kuwano K; Morrison K; Gatfield J; Hamamoto T; Clozel M
    J Med Chem; 2015 Sep; 58(18):7128-37. PubMed ID: 26291199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension.
    Shen L; Patel JA; Norel X; Moledina S; Whittle BJ; von Kessler K; Sista P; Clapp LH
    Biochem Pharmacol; 2019 Aug; 166():242-252. PubMed ID: 31158340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor.
    Benyahia C; Boukais K; Gomez I; Silverstein A; Clapp L; Fabre A; Danel C; Leséche G; Longrois D; Norel X
    Prostaglandins Other Lipid Mediat; 2013 Dec; 107():48-55. PubMed ID: 23850788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
    Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
    Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
    Honorato Pérez J
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
    Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
    PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of beraprost sodium (a PGI2 derivative) on chronic hypoxic pulmonary hypertension in the rat].
    Saito M; Tatsumi K; Kasahara Y; Tani T; Kuriyama T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1995 May; 33(5):497-504. PubMed ID: 7609334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents.
    Benyahia C; Ozen G; Orie N; Ledwozyw A; Louedec L; Li F; Senbel AM; Silverstein A; Danel C; Longrois D; Clapp LH; Norel X; Topal G
    Prostaglandins Other Lipid Mediat; 2015 Sep; 121(Pt A):46-52. PubMed ID: 26362969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery.
    Jones RL; Qian YM; Wise H; Wong HN; Lam WL; Chan HW; Yim AP; Ho JK
    J Cardiovasc Pharmacol; 1997 Apr; 29(4):525-35. PubMed ID: 9156364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the endothelial functions in monocrotaline-induced pulmonary hypertension.
    Sirmagul B; Ilgin S; Atli O; Usanmaz SE; Demirel-Yilmaz E
    Clin Exp Hypertens; 2013; 35(3):220-7. PubMed ID: 22967272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological characteristics and clinical study results of Selexipag (Uptravi
    Kuwano K; Kosugi K; Fuchikami C; Funaki S
    Nihon Yakurigaku Zasshi; 2021; 156(3):178-186. PubMed ID: 33952848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
    Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
    Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.